Healthcare's AI race heats up
Source: Business Insider ·
Eli Lilly is testing a new weight loss drug called retatrutide, and other companies like Ro are taking advantage of AI in their health tech products.
From the source
GLP-1 medications reduce appetite and slow down digestion.Svitlana Pietukhova/Getty ImagesThis post originally appeared in the Business Insider Today newsletter.You can sign up for Business Insider's daily newsletter here.Winning is all about losing when it comes to weight-loss drugs. Eli Lilly thinks it has a REAL loser on its hands.The pharma giant published results from its first clinical trial pitting retatrutide, a next-generation injectable medication awaiting regulatory approval, against Ozempic.Patients with type 2 diabetes using retatrutide, or "reta" as some know it, lost, on average, more than twice as much weight (47 pounds) as those on the highest dose of Ozempic (21 pounds) during 16 months.BI's Hilary Brueck has all the details on the trial here.Dubbed "King Kong" or "triple G" because it mimics three different hormones, some believe the weight loss that users experience using reta could rival bariatric surgery.Some of you might be well aware of reta. Even though it's…